Henry W. Long, PhD

I received a BS from MIT and a PhD in Chemistry from UC Berkeley.  As a member of the pharmaceutical industry for more than 10 years I am well versed in target selection and validation in cancer biology and many other disease areas. In addition, I have spent a considerable amount of time evaluating and employing a variety of technologies for identifying genomic biomarkers in numerous clinical and pre-clinical programs. At Dana-Farber Cancer Institute, I acquired extensive experience in cancer epigenetics and have contributed to the characterization of the androgen receptor cistrome in prostate cancer and have applied single cell appraoches to study intratumor heterogeneity. As the Scientific Director of the Center for Functional Cancer Epigenetics, I have applied state of the art epigenetics technologies to identify enhancers and other non-coding annotations in the human genome. Additionally, the Center has been developed and applied state of the art analysis pipelines to extract value from complex integrative genomics studies and support reproducible research efforts.